Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2026)

Neurocrine Biosciences' Tax Provisions history runs 8 years deep, the most recent figure standing at $48.9 million for Q1 2026.

• Quarterly Tax Provisions rose 619.12% year-over-year to $48.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.9 million (up 67.64% YoY) and the FY2025 annual result came in at $226.8 million, up 56.74% from the prior year.
• Tax Provisions was $48.9 million for Q1 2026 at Neurocrine Biosciences, down from $85.7 million in the prior quarter.
• Across five years, Tax Provisions topped out at $85.7 million in Q4 2025 and bottomed at -$26.7 million in Q1 2023.
• A 5-year average of $33.1 million and a median of $32.5 million in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions sank 456.0% — and 2026, when it jumped 619.12%.
• Neurocrine Biosciences' Tax Provisions stood at $28.9 million in 2022, then surged by 74.74% to $50.5 million in 2023, then rose by 17.82% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025, then slumped by 42.94% to $48.9 million in 2026.
• Business Quant data shows NBIX's Tax Provisions at $48.9 million in Q1 2026, $85.7 million in Q4 2025, and $82.3 million in Q3 2025.